ABSTRACT
Myasthenia gravis (MG) is a rare autoimmune disease mediated by antibodies directed against a component of the striated skeletal muscle postsynaptic membrane. Case reports and a case series document rapid and durable responses following autologous hematopoietic stem cell transplantation (HSCT) in a limited number of MG patients that had severe symptoms refractory to cholinesterase inhibitors and immunomodulatory treatments. Given the limited information, HSCT for MG should be performed at centers experienced in HSCT for autoimmune disease, with the outcomes published.
